Dementia and Alzheimer’s Disease Treatment Market to Grow with a CAGR of 6.56% through 2030

Surge in research and development activities is expected to drive the Global Dementia and Alzheimer’s Disease Treatment Market growth in the forecast period, 2026-2030.

According to TechSci Research report, “Dementia and Alzheimer’s Disease Treatment Market - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Dementia and Alzheimer’s Disease Treatment Market stood at USD 12.17 Billion in 2024 and is anticipated to grow with a CAGR of 6.56% through 2030. Initiatives taken by government based on dementia and alzheimer’s disease treatment has led to favorable market conditions for the Global Dementia and Alzheimer’s Disease Treatment Market. Several factors contribute to the growth of various dementia and alzheimer’s disease treatment products.

Over the past decade, there has been a significant increase in the number of clinical trials aimed at addressing the underlying causes of Alzheimer’s disease rather than merely alleviating its symptoms. This includes the development of monoclonal antibodies that target beta-amyloid and tau proteins key contributors to the progression of the disease. Recent regulatory approvals of some of these biologics have marked a turning point, demonstrating that sustained R&D investment can lead to meaningful advances in disease management. These developments have not only brought hope to millions of patients and families but have also validated ongoing scientific exploration and encouraged further industry engagement.

In the United States, the federal government enacted the National Alzheimer’s Project Act (NAPA), which provides a comprehensive framework to coordinate research, clinical care, and public awareness. This legislation has significantly increased federal funding for Alzheimer’s research, with annual allocations exceeding billions of dollars in recent years. The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have further advanced these efforts through initiatives that support the development of diagnostic tools, promote early detection, and provide community-based care solutions. Additionally, policies such as the 21st Century Cures Act have simplified regulatory pathways, encouraging innovation in dementia therapeutics.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Dementia and Alzheimer’s Disease Treatment Market”

The Global Dementia and Alzheimer’s Disease Treatment Market is segmented into drug class, distribution channel, regional distribution, and company.

Based on Drug Class, Memantine have emerged as the dominating segment in the Global Dementia and Alzheimer’s Disease Treatment Market in 2024. One of the key factors contributing to memantine’s dominant market position is its distinct mechanism of action. As an NMDA (N-methyl-D-aspartate) receptor antagonist, memantine regulates the activity of glutamate, a neurotransmitter involved in learning and memory. By preventing overstimulation of these receptors an effect thought to contribute to neuronal damage memantine helps to preserve cognitive function and delay disease progression in patients with more advanced Alzheimer’s symptoms. This therapeutic benefit has been widely recognized by clinicians, making it a standard treatment option globally.

Based on Region, Asia Pacific have emerged as the fastest growing region in the Global Dementia and Alzheimer’s Disease Treatment Market in 2024. Governments in the region are actively responding to this public health challenge through policy initiatives, expanded healthcare infrastructure, and increased funding for neurological research. For instance, national dementia strategies in countries like Japan and South Korea aim to enhance early diagnosis, improve access to medication, and provide integrated care services. Additionally, growing awareness among both healthcare providers and the general population is contributing to earlier intervention and greater demand for therapeutic options.

Major companies operating in Global Dementia and Alzheimer’s Disease Treatment Market are:

• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer, Inc.
• Ono Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• H. Lundbeck A/S
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Eli Lilly and Company
• Corium, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“In addition to therapeutic applications, nanotechnology is revolutionizing the diagnostic landscape through the use of nanosensors and nanoprobes. These tools are capable of detecting minute concentrations of disease biomarkers in cerebrospinal fluid, blood, or brain tissue, enabling ultrasensitive and early-stage diagnosis. Gold nanoparticles and quantum dots, for instance, are being explored in the development of advanced imaging agents for use in PET and MRI scans, offering high-resolution visualization of neural degeneration”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Dementia and Alzheimer’s Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, Combination Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Dementia and Alzheimer’s Disease Treatment Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Dementia and Alzheimer’s Disease Treatment Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]